Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Xenon Pharmaceuticals (Nasdaq: XENE) announced equity inducement grants on December 4, 2025 to five new non-officer employees totaling 39,250 share options. The options carry an exercise price of $44.61, equal to Xenon’s closing share price on the grant date, vest over four years (25% after one year, then monthly vesting), and have a 10-year term. Grants were approved by the Compensation Committee and issued under Nasdaq Listing Rule 5635(c)(4) and the company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Terms are subject to each option agreement and continued service; the company highlighted its lead asset azetukalner in Phase 3 and earlier-stage ion channel programs.
Xenon (Nasdaq: XENE) will host an investor webinar on December 10, 2025, 10:00 AM ET to review data presented at the American Epilepsy Society Annual Meeting (AES 2025).
The webinar covers new long-term results from the ongoing X-TOLE open-label extension of azetukalner in focal onset seizures, real-world data on depression and titration burden in epilepsy, and an update on preparations for commercialization of azetukalner. A live webcast and replay will be available on the company Investors site.
Xenon Pharmaceuticals (Nasdaq: XENE) will present seven posters at AES 2025 (Dec 5–9, 2025) highlighting long-term clinical and preclinical epilepsy data.
Key highlights include a ≥48‑month interim analysis from the ongoing X-TOLE open‑label extension of azetukalner in focal epilepsy, characterization of long-term seizure‑freedom epochs, patient‑reported depression and titration burden studies, and preclinical NaV1.1 data in Dravet mice reporting suppression of spontaneous seizures, prevention of SUDEP, and increased long‑term potentiation.
Sessions, symposium and a scientific exhibit will be held Dec 6–8 in Atlanta; posters available after live presentations.
Xenon Pharmaceuticals (Nasdaq: XENE) will present at two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 3:20 PM ET and the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 AM GMT / 6:30 AM ET. Webcasts are mentioned and will be posted for replay when available. Dates and times are subject to change.
The release reiterates Xenon’s focus on neuroscience drug discovery and development, notes lead molecule azetukalner is in Phase 3 for epilepsy, MDD and BPD, and references Phase 1 programs for Nav1.7 and Kv7 targeting pain. Investor materials and webcast links will be available on Xenon’s Investors webpage.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q3 2025 results on Nov 3, 2025, and provided a business update focused on late‑stage development of azetukalner and early‑stage ion channel programs.
Key points: Phase 3 X-TOLE2 completed randomization of 380 patients with topline data expected early 2026. X-NOVA2/X-NOVA3 (MDD) and X-CEED (BPD) continue to recruit. Phase 1 studies underway for XEN1701 (Nav1.7) and XEN1120 (Kv7). Cash, cash equivalents and marketable securities were $555.3M at Sept 30, 2025 with runway anticipated into 2027.
Xenon Pharmaceuticals (Nasdaq: XENE) will report third quarter 2025 financial results and provide a business update after U.S. market close on Monday, November 3, 2025 at 4:30 PM ET (1:30 PM PT). A live webcast and replay will be available on Xenon’s investors website; dial-in details and conference ID are provided for callers.
The company is a neuroscience-focused biopharmaceutical developer; its lead molecule azetukalner is in Phase 3 trials for epilepsy, major depressive disorder and bipolar depression, and Xenon also has Phase 1 Kv7 and Nav1.7 pain programs.
Xenon Pharmaceuticals (Nasdaq: XENE) announced the appointment of Tucker Kelly as Chief Financial Officer effective October 15, 2025. Kelly brings more than 25 years of finance and commercialization experience and previously served as CFO at Deciphera, where he helped oversee a $2.4B acquisition by Ono in 2024. The company granted Kelly an option to purchase 225,000 common shares at an exercise price of $41.90 and 30,000 restricted share units; the option vests over four years and has a 10-year term. Management says Kelly will support preparations for anticipated commercialization of lead candidate azetukalner and upcoming topline data from the X-TOLE2 Phase 3 epilepsy study.
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to seven new non-officer employees totaling 77,750 share options with an exercise price of $39.20 per share, equal to the closing price on the grant date. Grants were approved by the Compensation Committee with an effective date of October 2, 2025 and are intended as inducements under Nasdaq Listing Rule 5635(c)(4). Options vest over four years (25% at one year, then monthly 1/36th) and have a 10-year term, subject to the company’s 2025 Inducement Equity Incentive Plan and standard option agreement terms.
Business context: Xenon is a neuroscience-focused biopharmaceutical company advancing azetukalner in Phase 3 for epilepsy, MDD, and BPD and early-stage Kv7 and Nav1.7 programs in Phase 1 for pain.
Xenon Pharmaceuticals (NASDAQ:XENE) has announced an upcoming investor webinar scheduled for October 6, 2025, focused on their early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.
The webinar, titled "Developing Novel Non-Opioid Treatments for Pain," will be held from 11:30 AM to 12:30 PM Eastern Time. Investors can submit questions during the live webinar via chat or in advance by email. The company's lead molecule, azetukalner, is currently in Phase 3 trials for epilepsy, major depressive disorder, and bipolar depression, while their pain treatment programs are in Phase 1 development.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced equity inducement grants to seven new non-officer employees, totaling 55,300 share options. The options, approved by the Compensation Committee, were granted at an exercise price of $38.60 per common share, matching the closing price on August 28, 2025.
The options vest over four years, with 25% vesting after one year and the remaining vesting monthly over three years. Each option has a 10-year term under the Company's 2025 Inducement Equity Incentive Plan.
Xenon is advancing azetukalner, their lead molecule, in Phase 3 trials for epilepsy, major depressive disorder, and bipolar depression, while also developing early-stage potassium and sodium channel modulators in Phase 1 for pain treatment.